C-Rad AB (publ) (CRAD-B)
Stockholm Exchange · Sweden · prices in SEK · close of 19 Oct 2026
Key indicators
| Last close | SEK 27.90 |
|---|---|
| 52-week range | 24.53 – 39.40 |
| Return, 1 month / 3 months | −19.1% / −25.6% |
| Return, 1 year / 3 years | −13.9% / −7.3% |
| Trend | Below its 200-day average |
| RSI (14) | 29 |
| Volatility (1 year) | 38.5% |
| Worst drawdown (1 year) | -29.6% |
| Average daily value traded | 0.67M SEK |
| Dividend yield | 0.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
C-Rad AB is a Swedish medical technology company based in Uppsala that develops and supplies equipment used in radiation therapy for cancer patients. Its products include systems for patient positioning and monitoring during treatment, along with software that helps radiotherapy teams set up and track patients accurately. The company's customers are hospitals and cancer treatment centres, and its equipment is used in radiotherapy departments in several countries around the world.
The shares are listed on the Stockholm Exchange in Sweden under the code CRAD-B, and the price on this page is in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
C-Rad AB (publ) (CRAD-B) trades on the Stockholm Exchange in Sweden. It last closed at SEK 27.90 on 19 October 2026.
Its price-based Market X-Ray is 51 out of 100 (a fair price profile), ranking 456 of 911 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 13.9% and over the last three months it fell 25.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 53 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -13.2% | ||
| From 52-week high | -28.1% | ||
| Momentum | 49 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -25.6% | ||
| 6-month return | 1.8% | ||
| 12-month return, skipping the last month | 6.5% | ||
| Stability (higher is calmer) | 67 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 38.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.6% | ||
| Liquidity | 54 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.67M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | 3 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.4% | ||
| Years with dividends | 1 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.2% |
|---|---|
| 1 month | −19.1% |
| 3 months | −25.6% |
| 6 months | +1.8% |
| 1 year | −13.9% |
| 3 years | −7.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 33.76 / 32.16 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.13 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 8 May 2026 | SEK 0.1000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.